죽상동맥경화증 시장 : 전략적 인사이트와 예측(2026-2031년)

The Global Atherosclerosis market is projected to grow at a CAGR of 3.0% over the forecast period, increasing from USD 35.4 billion in 2026 to USD 41.1 billion by 2031.

Atherosclerosis is a chronic cardiovascular condition characterized by the accumulation of lipids, cholesterol, inflammatory cells, and fibrous material within arterial walls, leading to plaque formation and reduced blood flow. The disease is a major underlying cause of coronary artery disease, stroke, peripheral artery disease, and other cardiovascular complications. As cardiovascular diseases remain among the leading causes of mortality worldwide, the demand for effective atherosclerosis diagnosis, prevention, and treatment solutions continues to increase. The growing burden of obesity, diabetes, hypertension, smoking, and sedentary lifestyles is further contributing to disease prevalence and market expansion.

The market is undergoing significant transformation due to advancements in pharmacological therapies and precision cardiovascular medicine. Statins continue to serve as the cornerstone of atherosclerosis management, while newer treatment options such as PCSK9 inhibitors, anti-inflammatory therapies, RNA-based lipid-lowering agents, and combination treatment regimens are expanding therapeutic possibilities. These innovations are helping healthcare providers achieve improved cholesterol control and cardiovascular risk reduction among high-risk patient populations.

Increasing awareness regarding preventive cardiovascular care is another important factor supporting market growth. Governments, healthcare providers, and public health organizations are investing in screening programs, cholesterol monitoring initiatives, and lifestyle modification campaigns to reduce cardiovascular risk factors before the onset of severe disease. Early diagnosis and proactive disease management are becoming central components of cardiovascular healthcare strategies.

Technological innovation is also enhancing disease management capabilities. Advanced imaging technologies, non-invasive diagnostic techniques, artificial intelligence-assisted risk assessment tools, and digital health platforms are improving the detection and monitoring of atherosclerotic disease. These developments enable earlier intervention and more personalized treatment approaches, supporting better long-term patient outcomes.

The market is further benefiting from increased healthcare expenditure and expanding access to cardiovascular treatment services in emerging economies. Improvements in healthcare infrastructure, insurance coverage, and access to specialty cardiovascular care are creating favorable conditions for market growth across developing regions.

North America currently represents the largest regional market due to high cardiovascular disease prevalence, advanced healthcare systems, strong pharmaceutical innovation, and widespread adoption of preventive care. Europe remains a significant market supported by established cardiovascular treatment programs and aging demographics. Asia Pacific is expected to witness the fastest growth due to rising cardiovascular disease incidence, healthcare modernization, increasing healthcare investments, and growing awareness of cardiovascular health.

Market Drivers

One of the primary drivers of the atherosclerosis market is the increasing prevalence of cardiovascular diseases globally. Rising rates of heart attacks, strokes, peripheral artery disease, and other cardiovascular complications associated with atherosclerosis are creating sustained demand for effective treatment and prevention strategies.

The growing aging population is another major growth driver. Older adults are at greater risk of developing atherosclerotic disease due to cumulative vascular damage and prolonged exposure to cardiovascular risk factors. Increasing life expectancy is expanding the patient population requiring long-term cardiovascular management.

Advancements in lipid-lowering therapies are significantly supporting market growth. The development of novel therapies beyond traditional statins is improving treatment outcomes for patients with elevated cardiovascular risk and treatment-resistant hypercholesterolemia.

The increasing emphasis on preventive healthcare is further accelerating market expansion. Healthcare systems are focusing on early diagnosis, cholesterol management, smoking cessation, dietary interventions, and cardiovascular risk reduction programs to reduce disease burden and healthcare costs.

Expansion of healthcare infrastructure in emerging economies is also contributing to market growth. Improved access to diagnostic services, cardiovascular specialists, and pharmaceutical therapies is increasing treatment rates and disease management capabilities.

Rising adoption of personalized medicine approaches and advanced diagnostic technologies is helping clinicians identify high-risk patients more effectively and optimize treatment strategies.

Market Restraints

Despite favorable growth prospects, the atherosclerosis market faces several challenges. One major restraint is the highly competitive nature of the pharmaceutical market. The widespread availability of generic cardiovascular drugs creates pricing pressure and limits revenue growth opportunities for branded therapies.

Patent expirations and generic competition continue to affect profitability across several therapeutic categories. As blockbuster cardiovascular drugs lose exclusivity, manufacturers face increasing pressure to differentiate newer treatment options.

Treatment adherence remains an important challenge. Atherosclerosis often requires lifelong therapy, lifestyle modifications, and regular monitoring. Poor patient compliance can reduce treatment effectiveness and increase the risk of adverse cardiovascular events.

The high cost of some innovative therapies may limit accessibility in certain healthcare systems. Advanced biologics and specialty cardiovascular treatments may create reimbursement challenges and affordability concerns, particularly in developing regions.

Late diagnosis of cardiovascular disease remains another obstacle. Many patients remain asymptomatic until advanced disease develops, reducing opportunities for early intervention and preventive management.

Regulatory requirements for cardiovascular drug approval and long-term safety evaluation can also increase development timelines and costs for pharmaceutical companies.

Technology and Segment Insights

The market can be segmented by drug class into statins, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, diuretics, and other cardiovascular therapies. Statins continue to dominate the market due to their established role in cholesterol reduction and cardiovascular risk management.

By therapy type, drug therapy accounts for the largest market share because pharmacological treatment remains the foundation of atherosclerosis management across most patient populations. Interventional procedures and device-based therapies are primarily utilized in advanced disease cases.

Based on diagnosis, imaging technologies, Doppler ultrasound, ankle-brachial index testing, electrocardiography, echocardiography, blood biomarker analysis, and advanced cardiovascular screening techniques play important roles in disease detection and monitoring.

By treatment setting, hospitals account for a substantial market share due to their comprehensive cardiovascular care capabilities. Specialty cardiovascular clinics, ambulatory care centers, and home healthcare services also contribute significantly to disease management.

Emerging technologies such as artificial intelligence-assisted diagnostics, predictive analytics, digital therapeutics, wearable monitoring devices, and precision medicine platforms are expected to further enhance disease management and patient outcomes.

Competitive and Strategic Outlook

The competitive landscape of the atherosclerosis market is characterized by ongoing pharmaceutical innovation, strategic partnerships, and increasing investment in cardiovascular research. Major companies are focusing on the development of next-generation lipid-lowering therapies, anti-inflammatory treatments, and precision medicine solutions aimed at improving cardiovascular outcomes.

Organizations are investing heavily in research and development to address unmet clinical needs, particularly among patients who do not achieve optimal outcomes with traditional therapies. Novel drug classes and combination treatment approaches are expected to play increasingly important roles in future market growth.

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and healthcare organizations are supporting innovation and accelerating clinical development programs. These partnerships facilitate biomarker discovery, therapeutic advancement, and commercialization efforts.

The market is also witnessing increased adoption of digital health technologies and telemedicine platforms. Remote monitoring, patient engagement applications, and data-driven cardiovascular management programs are helping improve treatment adherence and long-term disease control.

Emerging markets represent significant growth opportunities due to expanding healthcare infrastructure, increasing cardiovascular disease prevalence, and improving access to treatment services. Countries across Asia Pacific and Latin America are expected to contribute substantially to future market expansion.

Future competition is expected to focus on therapeutic efficacy, safety profiles, affordability, patient adherence, and personalized treatment strategies. Companies capable of delivering innovative and cost-effective cardiovascular solutions may strengthen their long-term market positions.

Conclusion

The atherosclerosis market is expected to experience sustained growth as cardiovascular diseases continue to represent a major global healthcare burden. Rising disease prevalence, increasing aging populations, expanding preventive healthcare initiatives, and ongoing innovation in cardiovascular therapeutics are supporting long-term market development.

Although challenges related to generic competition, treatment adherence, healthcare affordability, and regulatory complexity remain, continued advancements in lipid-lowering therapies, precision medicine, digital health technologies, and early diagnostic capabilities are expected to strengthen market expansion. As healthcare systems increasingly prioritize cardiovascular disease prevention and management, the atherosclerosis market will remain a critical component of the global cardiovascular healthcare industry.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Demand Drivers
• 1.3 Strategic Market Shift
• 1.4 Therapeutic and Interventional Evolution
• 1.5 Regional Demand Overview
• 1.6 Competitive Landscape Snapshot
• 1.7 Future Outlook and Industry Transformation

2. Disease & Epidemiology Analysis

• 2.1 Overview of Atherosclerosis
• 2.2 Pathophysiology and Plaque Development
• 2.3 Disease Progression and Clinical Burden
• 2.4 Epidemiology Analysis
  • 2.4.1 Global Prevalence and Incidence
  • 2.4.2 Age-Wise Disease Burden
  • 2.4.3 Gender-Based Trends
  • 2.4.4 Mortality and Morbidity Trends
• 2.5 Risk Factor Analysis
  • 2.5.1 Hypertension
  • 2.5.2 Hyperlipidemia
  • 2.5.3 Diabetes Mellitus
  • 2.5.4 Obesity
  • 2.5.5 Smoking and Sedentary Lifestyle
  • 2.5.6 Chronic Kidney Disease
• 2.6 Disease Subtype Analysis
  • 2.6.1 Coronary Atherosclerosis
  • 2.6.2 Carotid Artery Atherosclerosis
  • 2.6.3 Peripheral Artery Atherosclerosis
  • 2.6.4 Aortic Atherosclerosis
• 2.7 Diagnostic Pathways and Screening Trends
• 2.8 Unmet Clinical Needs

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Cardiovascular Disease Burden
  • 3.1.2 Increasing Adoption of Lipid-Lowering Therapies
  • 3.1.3 Expansion of Minimally Invasive Vascular Interventions
  • 3.1.4 Growing Utilization of AI-Enabled Cardiovascular Diagnostics
• 3.2 Market Restraints
  • 3.2.1 High Cost of Advanced Biologic Therapies
  • 3.2.2 Limited Access to Preventive Cardiovascular Screening
  • 3.2.3 Stringent Regulatory and Outcome Validation Requirements
• 3.3 Market Opportunities
  • 3.3.1 Expansion of PCSK9 Inhibitors and Novel Lipid Therapies
  • 3.3.2 Growth in Digital Cardiovascular Monitoring
  • 3.3.3 Emerging Demand for Personalized Cardiovascular Risk Management
  • 3.3.4 Expansion Across Emerging Healthcare Markets
• 3.4 Supply Chain Analysis
• 3.5 Pricing and Reimbursement Trends
• 3.6 Healthcare Infrastructure Impact

4. Commercial & Market Access

• 4.1 Commercialization Framework
• 4.2 Reimbursement Landscape
• 4.3 Market Access Challenges
• 4.4 Payer and Hospital Procurement Trends
• 4.5 Role of Preventive Cardiology Programs
• 4.6 Patient Adherence and Long-Term Therapy Utilization

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends in Atherosclerosis Management
• 5.2 Evolution of Lipid-Lowering Therapies
• 5.3 Pipeline Landscape Overview
• 5.4 Pipeline Candidates by Clinical Phase
  • 5.4.1 Phase I Pipeline Candidates
  • 5.4.2 Phase II Pipeline Candidates
  • 5.4.3 Phase III Pipeline Candidates
• 5.5 Mechanism of Action Analysis
  • 5.5.1 PCSK9 Inhibitors
  • 5.5.2 siRNA-Based Lipid Therapies
  • 5.5.3 Anti-Inflammatory Cardiovascular Therapies
  • 5.5.4 CETP Inhibitors
  • 5.5.5 Gene Editing and RNA-Based Therapies
• 5.6 Innovation in Vascular Imaging and Diagnostics
• 5.7 AI and Predictive Cardiovascular Analytics

6. Treatment Landscape

• 6.1 Current Standard of Care
• 6.2 Pharmacological Treatment Landscape
  • 6.2.1 Statins
  • 6.2.2 PCSK9 Inhibitors
  • 6.2.3 Antiplatelet Agents
  • 6.2.4 Anticoagulants
  • 6.2.5 Antihypertensive Therapies
  • 6.2.6 Anti-Inflammatory Therapies
• 6.3 Interventional Treatment Landscape
  • 6.3.1 Coronary Stenting
  • 6.3.2 Peripheral Vascular Interventions
  • 6.3.3 Carotid Artery Stenting
  • 6.3.4 Atherectomy Systems
• 6.4 Diagnostic and Monitoring Technologies
• 6.5 Lifestyle and Preventive Management Approaches

7. Global Atherosclerosis Market Size & Forecast

• 7.1 Global Market Overview
• 7.2 Historical Market Analysis
• 7.3 Forecast Analysis (2026-2031)
• 7.4 Market Forecast by Therapy Type
• 7.5 Market Forecast by Drug Class
• 7.6 Market Forecast by Indication
• 7.7 Market Forecast by Region

8. Global Atherosclerosis Market Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Pharmacological Therapies
  • 8.1.2 Drug-Eluting Stents
  • 8.1.3 Atherectomy Devices
  • 8.1.4 Vascular Imaging Systems
  • 8.1.5 Digital Cardiovascular Monitoring Platforms
• 8.2 By Drug Class
  • 8.2.1 Statins
  • 8.2.2 PCSK9 Inhibitors
  • 8.2.3 Antiplatelet Agents
  • 8.2.4 Anticoagulants
  • 8.2.5 Antihypertensive Agents
  • 8.2.6 Anti-Inflammatory Therapies
  • 8.2.7 Others
• 8.3 By Indication
  • 8.3.1 Coronary Artery Disease
  • 8.3.2 Carotid Artery Disease
  • 8.3.3 Peripheral Artery Disease
  • 8.3.4 Aortic Atherosclerosis
  • 8.3.5 Chronic Total Occlusion

9. Geographical Analysis

• 9.1 North America
  • 9.1.1 Market Size and Growth Trends
  • 9.1.2 Cardiovascular Disease Burden
  • 9.1.3 Regulatory Environment
  • 9.1.4 Competitive Intensity
  • 9.1.5 Technology Adoption Trends
• 9.2 Europe
  • 9.2.1 Market Size and Growth Trends
  • 9.2.2 Preventive Cardiology Adoption
  • 9.2.3 Regulatory Environment
  • 9.2.4 Competitive Intensity
  • 9.2.5 Reimbursement Trends
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Growth Trends
  • 9.3.2 Rising Metabolic Disease Burden
  • 9.3.3 Regulatory Environment
  • 9.3.4 Competitive Intensity
  • 9.3.5 Healthcare Infrastructure Expansion
• 9.4 Latin America
  • 9.4.1 Market Size and Growth Trends
  • 9.4.2 Cardiovascular Screening Trends
  • 9.4.3 Regulatory Environment
  • 9.4.4 Competitive Intensity
  • 9.4.5 Access Challenges
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Growth Trends
  • 9.5.2 Chronic Disease Burden
  • 9.5.3 Regulatory Environment
  • 9.5.4 Competitive Intensity
  • 9.5.5 Infrastructure Modernization

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 United States Regulatory Framework
  • 11.1.1 FDA Drug Approval Pathways
  • 11.1.2 Cardiovascular Device PMA and 510(k) Pathways
  • 11.1.3 Post-Market Cardiovascular Surveillance
• 11.2 Europe Regulatory Framework
  • 11.2.1 EMA Drug Evaluation Process
  • 11.2.2 EU MDR Compliance
  • 11.2.3 Cardiovascular Outcome Monitoring
• 11.3 Japan Regulatory Framework
  • 11.3.1 PMDA Cardiovascular Therapy Approval
  • 11.3.2 Long-Term Device Safety Assessment
• 11.4 India Regulatory Framework
  • 11.4.1 CDSCO Drug and Device Regulation
  • 11.4.2 Pharmacovigilance Requirements
• 11.5 China Regulatory Framework
  • 11.5.1 NMPA Approval Process
  • 11.5.2 Local Clinical Validation Requirements
• 11.6 Global Reimbursement and HTA Trends
• 11.7 Regulatory Impact on Innovation

12. Competitive Landscape

• 12.1 Market Competition Overview
• 12.2 Strategic Positioning Analysis
• 12.3 Product Portfolio Benchmarking
• 12.4 Partnership and Collaboration Trends
• 12.5 Mergers and Acquisitions
• 12.6 Innovation and Pipeline Competition
• 12.7 AI and Digital Cardiovascular Integration Trends

13. Company Profiles

• 13.1 Amgen
  • 13.1.1 Company Overview
  • 13.1.2 Approved Product Portfolio
    • 13.1.2.1 Repatha (evolocumab)
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Candidates and Clinical Development
  • 13.1.5 Financial Performance
  • 13.1.6 Strategic Developments
• 13.2 Novartis
  • 13.2.1 Company Overview
  • 13.2.2 Approved Product Portfolio
    • 13.2.2.1 Leqvio (inclisiran)
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Candidates and Clinical Development
  • 13.2.5 Strategic Developments
• 13.3 Sanofi
  • 13.3.1 Company Overview
  • 13.3.2 Approved Product Portfolio
    • 13.3.2.1 Praluent (alirocumab)
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Candidates and Clinical Development
  • 13.3.5 Strategic Developments
• 13.4 Regeneron Pharmaceuticals
  • 13.4.1 Company Overview
  • 13.4.2 Approved Product Portfolio
    • 13.4.2.1 Praluent (alirocumab - alliance commercialization)
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Candidates and Clinical Development
  • 13.4.5 Strategic Developments
• 13.5 Abbott Laboratories
  • 13.5.1 Company Overview
  • 13.5.2 Approved Device Portfolio
    • 13.5.2.1 XIENCE Drug-Eluting Stent System
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline and Innovation Programs
  • 13.5.5 Strategic Developments
• 13.6 Boston Scientific
  • 13.6.1 Company Overview
  • 13.6.2 Approved Device Portfolio
    • 13.6.2.1 Eluvia Drug-Eluting Vascular Stent System
    • 13.6.2.2 Ranger Drug-Coated Balloon
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline and Innovation Programs
  • 13.6.5 Strategic Developments
• 13.7 Medtronic
  • 13.7.1 Company Overview
  • 13.7.2 Approved Device Portfolio
    • 13.7.2.1 HawkOne Atherectomy System
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline and Innovation Programs
  • 13.7.5 Strategic Developments
• 13.8 Philips
  • 13.8.1 Company Overview
  • 13.8.2 Approved Imaging Portfolio
    • 13.8.2.1 IntraSight Interventional Applications
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline and Innovation Programs
  • 13.8.5 Strategic Developments
• 13.9 Terumo Corporation
  • 13.9.1 Company Overview
  • 13.9.2 Approved Device Portfolio
    • 13.9.2.1 Misago Peripheral Stent System
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline and Innovation Programs
  • 13.9.5 Strategic Developments
• 13.10 BD
  • 13.10.1 Company Overview
  • 13.10.2 Approved Device Portfolio
    • 13.10.2.1 Rotarex Atherectomy System
    • 13.10.2.2 Lutonix Drug-Coated Balloon
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline and Innovation Programs
  • 13.10.5 Strategic Developments

14. Future Outlook

• 14.1 Evolution of Preventive Cardiovascular Care
• 14.2 Future of RNA-Based and Gene Therapies
• 14.3 AI-Driven Cardiovascular Risk Prediction
• 14.4 Future of Personalized Lipid Management
• 14.5 Emerging Interventional Technologies
• 14.6 Long-Term Strategic Industry Outlook

15. Methodology

• 15.1 Research Methodology Overview
• 15.2 Data Collection Framework
• 15.3 Primary Research Methodology
• 15.4 Secondary Research Sources
• 15.5 Forecasting Assumptions
• 15.6 Data Validation and Triangulation
• 15.7 Regulatory and Clinical Trial Source Validation
• 15.8 Limitations and Scope of Study